Protection against cutaneous leishmaniasis in outbred vervet monkeys using a recombinant histone H1 antigen.
Fiche du document
2003
- doi: 10.1086/378677
- issn: 0022-1899
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1086/378677
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/14551897
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pissn/0022-1899
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_CAC86D46812C4
info:eu-repo/semantics/openAccess , Copying allowed only for non-profit organizations , https://serval.unil.ch/disclaimer
Sujets proches
Haplorhini Infectious diseases Fauna Native fauna Native animals Beasts Wildlife Wild animals Animal kingdomCiter ce document
S. Masina et al., « Protection against cutaneous leishmaniasis in outbred vervet monkeys using a recombinant histone H1 antigen. », Serveur académique Lausannois, ID : 10.1086/378677
Métriques
Partage / Export
Résumé
Infection with Leishmania major parasites results in the development of cutaneous ulcerative lesions on the skin. We investigated the protective potential of a single, recombinant histone H1 antigen against cutaneous leishmaniasis in an outbred population of vervet monkeys, using Montanide adjuvant. Protection was assessed by challenging the animals with a mixture of vector sand fly salivary-gland lysate and a low dose of in vitro-derived parasites, thus more closely mimicking natural infection induced by L. major. The course of infection in immunized monkeys was compared with that of animals that had healed from a primary infection and were immune. The monkeys immunized with recombinant histone H1 showed a reduced development of lesion size, compared with controls. Our study therefore illustrates the potential use of histone H1 as a vaccine candidate against cutaneous leishmaniasis in humans.